Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NL-OMON23693
- Lead Sponsor
- Exelixis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 760
Inclusion Criteria
oHistological or cytological diagnosis of hepatocellular carcinoma
oThe subject has disease that is not amenable to a curative treatment approach
Exclusion Criteria
oFibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
oReceipt of more than 2 prior systemic therapies for advanced hepatocellular carcinoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression-free survival, objective response rate